21-DAY DOSING REGIMEN FOR FUSION PROTEINS COMPRISING FACTOR IX AND HUMAN ALBUMIN FOR PROPHYLACTIC TREATMENT OF HEMOPHILIA AND METHODS THEREOF

• 收藏
• 分享

专利权人:

CSL Behring Lengnau AG

发明人:

Yanyan LI,Debra BENSEN-KENNEDY,Iris JACOBS,Christine VOIGT

申请号：

US16626153

公开号：

US20200115436A1

申请日:

2018.06.29

申请国别(地区):

US

年份:

2020

代理人:

摘要：

The present invention relates to prophylactic dosing regimens with about 90-110 IU/kg long-acting factor IX (human FIX-human albumin) in dosing intervals of about three weeks (e.g., 21 days).

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/